Literature DB >> 6827177

Kinetic analysis of D-xylose absorption in normal subjects and in patients with chronic renal failure.

R M Craig, P Murphy, T P Gibson, A Quintanilla, G C Chao, C Cochrane, A Patterson, A J Atkinson.   

Abstract

D-Xylose kinetics were studied in 12 normal subjects and in nine patients with chronic renal failure requiring dialysis (five hemodialysis and four peritoneal dialysis). None of the study subjects had demonstrable gastrointestinal disease. Doses of D-xylose were given intravenously (10 gm) and orally (25 gm) on different nondialysis days in order to determine the distribution and elimination kinetics and the absolute bioavailability of this compound. Our findings were as follows. (1) The nonrenal clearance of D-xylose is markedly reduced in chronic renal failure patients (43.3 vs. 90.9 ml/min, p less than 0.002). (2) D-Xylose is less completely absorbed in patients with chronic renal failure than in normal subjects (48.6% vs. 69.4%, p less than 0.01). (3) The absorption rate of D-xylose is slower in these patients than in normal subjects (0.555 hr-1 vs. 1.03 hr-1, p less than 0.05). (4) The absorption rate is positively correlated with the extent of D-xylose absorption (r = 0.49, p = 0.03). (5) Although peak D-xylose concentrations measured 1 hr after oral administration are well correlated with the extent of D-xylose absorption in normal subjects and in functionally anephric patients (r = 0.59, p less than 0.01), formal kinetic study is required to determine D-xylose bioavailability precisely because of the large variability in peak serum D-xylose concentrations and in the time required to reach these peak concentrations.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6827177

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  15 in total

1.  Effect of renal function on the bioavailability of ciprofloxacin.

Authors:  K I Plaisance; G L Drusano; A Forrest; M R Weir; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Pitfalls of pharmacokinetic dosage guidelines in renal insufficiency.

Authors:  K Turnheim
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Assessment of liver ability to biotransformation of antipyrine in uraemic patients on regular peritoneal dialysis treatment.

Authors:  A Grzegorzewska; Z Lowicki; E Chmara; A Mrozikiewicz; K Baczyk
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

4.  Urinary recovery of lactulose compared to D-xylose absorption kinetics in HIV patients with diarrhea and weight loss.

Authors:  S J Carlson; C Webster; R M Craig
Journal:  Dig Dis Sci       Date:  1997-12       Impact factor: 3.199

5.  D-xylose absorption test. Urine or blood?

Authors:  Y Peled; O Doron; H Laufer; Y Bujanover; T Gilat
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

6.  D-xylose hydrogen breath tests compared to absorption kinetics in human patients with and without malabsorption.

Authors:  S Carlson; R M Craig
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

7.  Performance of a new meter designed for assisted monitoring of blood glucose and point-of-care testing.

Authors:  Sandra Macrury; Aparna Srinivasan; John J Mahoney
Journal:  J Diabetes Sci Technol       Date:  2013-03-01

Review 8.  Clinical pharmacokinetics in organ transplant patients.

Authors:  R Venkataramanan; K Habucky; G J Burckart; R J Ptachcinski
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

9.  Influence of renal function on the pharmacokinetics of diacerein after a single oral dose.

Authors:  P Debord; K Louchahi; M Tod; A Cournot; G Perret; O Petitjean
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jan-Mar       Impact factor: 2.441

Review 10.  Clinical pharmacokinetics of diacerein.

Authors:  P Nicolas; M Tod; C Padoin; O Petitjean
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.